Immune effector mechanisms in malaria: An update focusing on human immunity.
Ann M MoormannChristina E NixonCatherine S ForconiPublished in: Parasite immunology (2019)
The past decade has witnessed dramatic decreases in malaria-associated mortality and morbidity around the world. This progress has largely been due to intensified malaria control measures, implementation of rapid diagnostics and establishing a network to anticipate and mitigate antimalarial drug resistance. However, the ultimate tool for malaria prevention is the development and implementation of an effective vaccine. To date, malaria vaccine efforts have focused on determining which of the thousands of antigens expressed by Plasmodium falciparum are instrumental targets of protective immunity. The antigenic variation and antigenic polymorphisms arising in parasite genes under immune selection present a daunting challenge for target antigen selection and prioritization, and is a given caveat when interpreting immune recall responses or results from monovalent vaccine trials. Other immune evasion strategies executed by the parasite highlight the myriad of ways in which it can become a recurrent infection. This review provides an update on immune effector mechanisms in malaria and focuses on our improved ability to interrogate the complexity of human immune system, accelerated by recent methodological advances. Appreciating how the human immune landscape influences the effectiveness and longevity of antimalarial immunity will help explain which conditions are necessary for immune effector mechanisms to prevail.
Keyphrases
- plasmodium falciparum
- endothelial cells
- healthcare
- primary care
- induced pluripotent stem cells
- type diabetes
- gene expression
- pluripotent stem cells
- systematic review
- cardiovascular disease
- cardiovascular events
- dna methylation
- type iii
- single cell
- immune response
- coronary artery disease
- quantum dots
- toxoplasma gondii
- loop mediated isothermal amplification